Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Lamotrigine
PCO Manufacturing Ltd.
N03AX; N03AX09
Lamotrigine
100 milligram(s)
Chewable/dispersible tablet
Other antiepileptics; lamotrigine
2012-09-14
_ _ _ _ PACKAGE LEAFLET: INFORMATION FOR THE USER LAMICTAL ® 25 MG CHEWABLE/DISPERSIBLE TABLETS LAMICTAL ® 50 MG CHEWABLE/DISPERSIBLE TABLETS LAMICTAL ® 100 MG CHEWABLE/DISPERSIBLE TABLETS lamotrigine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. − Keep this leaflet. You may need to read it again. − If you have any further questions, ask your doctor or pharmacist. − This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. − If you get any of the side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Lamictal is and what it is used for 2. What you need to know before you take Lamictal 3. How to take Lamictal 4. Possible side effects 5. How to store Lamictal 6. Contents of the pack and other information 1. WHAT LAMICTAL IS AND WHAT IT IS USED FOR Lamictal belongs to a group of medicines called _anti-epileptics_. It is used to treat two conditions — EPILEPSY and BIPOLAR DISORDER. LAMICTAL TREATS EPILEPSY by blocking the signals in the brain that trigger epileptic seizures (fits). • For adults and children aged 13 years and over, Lamictal can be used on its own or with other medicines, to treat epilepsy. Lamictal can also be used with other medicines to treat the seizures that occur with a condition called Lennox-Gastaut syndrome. • For children aged between 2 and 12 years, Lamictal can be used with other medicines, to treat those conditions. It can be used on its own to treat a type of epilepsy called typical absence seizures. LAMICTAL ALSO TREATS BIPOLAR DISORDER. People with bipolar disorder (sometimes called _manic depression_) have extreme mood swings, with periods of mania (excitement or euphoria) alternating with periods of depression (deep sadness or despair). For adults aged 18 years and over, Lamictal can be used on Read the complete document
Health Products Regulatory Authority 19 July 2023 CRN00DPXD Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lamictal 100 mg chewable/dispersible tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each Lamictal 100 mg chewable/dispersible tablet contains 100 mg lamotrigine. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Chewable/dispersible tablet. _Product imported from Spain and Germany_ White to off‑white square tablet with rounded corners with a blackcurrant odour, marked “GSCL7” on one side and “100” on the other. The tablets may be slightly mottled. 4 CLINICAL PARTICULARS As per PA1077/061/009 5 PHARMACOLOGICAL PROPERTIES As per PA1077/061/009 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS Calcium carbonate Low-substituted hydroxypropyl cellulose Aluminium magnesium silicate Sodium starch glycolate (Type A) Povidone K30 Saccharin sodium Magnesium stearate Blackcurrant flavour 6.2 INCOMPATIBILITIES Not applicable. 6.3 SHELF LIFE The shelf life expiry date of this product is the date shown on the container and outer carton of the product as marketed in the country of origin. 6.4 SPECIAL PRECAUTIONS FOR STORAGE This medicinal product does not require any special storage conditions. 6.5 NATURE AND CONTENTS OF CONTAINER Blister packs of 56 chewable/dispersible tablets contained in an outer carton. Health Products Regulatory Authority 19 July 2023 CRN00DPXD Page 2 of 2 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL No special requirements for disposal. 7 PARALLEL PRODUCT AUTHORISATION HOLDER PCO Manufacturing Ltd. Unit 10, Ashbourne Business Park Rath Ashbourne Co. Meath Ireland 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA0465/443/003 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Last of first authorisation: 14 th December 2012 Last updated: April 2016 Last updated: September 2018 Last updated: May 2019 10 DATE OF REVISION OF THE TEXT July 2023 Read the complete document